Investigating the association between allergic diseases and COVID-19 in 400 Iranian patients

Main Article Content

Amirhossein Darabi
Mohammadrezad Dehghanfard
Sara Jozan
Rahim Tahmasebi
Ali Movahed
Marjan Zamani
Shokrollah Farrokhi

Keywords

allergic diseases, GA2LEN, COVID-19, SARS-CoV-2, underlying diseases

Abstract

Introduction: Allergic diseases could play a role of a predisposing factor for coronavirus dis-ease 2019 (COVID-19). The aim of this study was to investigate allergic comorbidity and its association in COVID-19 patients.


Methods: Demographic data, clinical manifestations, laboratory reports, and radiologic findings, together with underlying comorbidity of patients, were studies. Allergic diseases were identified by using the standard GA2LEN questionnaire. The severity of COVID-19 was assessed by a visual analog scale (VAS) and an intensive care unit (ICU) report.


Results: Out of 400 COVID-19 patients admitted in the hospital, 158 (39.5%) presented with different allergic diseases, and a reverse association was observed between having allergic comorbidity and severity of COVID-19 infection (P = 0.005, relative risk = 0.96; 95% Confidence Interval (95% CI): 0.77–1.19). The respective frequency of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS), atopic dermatitis, chronic urticaria, and food or drug allergy was 7.3%, 16%, 1.8%, 5%, 10% and 13.3%. Significantly, only AR was reversely associated with the severity of COVID-19 (P = 0.02, relative risk = 0.45; 95% CI: 0.77–1.19). Additionally, 43% of the patients presented hypoxemia, and 93.5% had chest CT scan involvement. Interestingly, patients with allergic diseases had significantly lower hypoxemia and chest CT involvement as compared with non-allergic patients (P = 0.002 and 0.003, respectively).


Conclusion: The results of this study established that allergic diseases were not determined to be a predisposing factor for the severe acute respiratory syndrome (SARS) due to coronavirus 2 (SARS-CoV-2) infection. Significantly, AR patients developed mild clinical manifestations of COVID-19 and admitted to ICU as compared to non-AR patients.

Abstract 271 | PDF Downloads 236 XML Downloads 8 HTML Downloads 4

References

1. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020, Jul;75(7):1742–52. https://doi.org/10.1111/all.14309
2. Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: A single center study. J Clin Virol 2020, Jun;127:104378. https://doi.org/10.1016/j.jcv.2020.104378
3. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020, Apr;92(4):418–23. https://doi.org/10.1002/jmv.25681
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, Jan;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
5. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020,Jul; 75(7):1730–41. https://doi.org/10.1111/all.14238
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020, Mar;395(10229):1011–88, e54–e61. https://doi.org/10.1016/S0140-6736(20)30566-3
7. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19
in the New York City area. JAMA. 2020;323(20):2052–59. https://doi.org/10.1001/jama.2020.6775
8. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med (NEJM). 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032
9. Kim S, Jung CG, Lee JY, Kim G, Choi SW, Jin HJ, et al. Characterization of asthma and risk factors for delayed SARS‐CoV‐2 clearance in adult COVID‐19 inpatients in Daegu. Allergy. 2021, Mar;76(3):918–21. https://doi.org/10.1111/all.14609
10. Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020, Oct;75(10):2503–41. https://doi.org/10.1111/all.14449
11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020, Feb;395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7
12. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—Case series. New Engl J Med (NEJM). 2020;382(21):2012–22. https://doi.org/10.1056/NEJMoa2004500
13. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020, Jun;329(21):2195-98. https://doi.org/10.1001/jama.2020.7202
14. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–14.e4. https://doi.org/10.1016/j.jaci.2020.06.010
15. Bousquet J, Burney P, Zuberbier T, Cauwenberge PV, Akdis C, Bindslev‐Jensen C, et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma "epidemic". Allergy. 2009;64(7):969–77. https://doi.org/10.1111/j.1398-9995.2009.02059.x
16. Greenberg SB, editor. Respiratory viral infections: Update on human rhinovirus and coronavirus infections. Seminars in respiratory and critical care medicine. New York, NY: Thieme; 2016.
17. Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013;4:293. https://doi.org/10.3389/fmicb.2013.00293
18. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;118(2):271–80. https://doi.org/10.1016/j.cell.2020.02.052
19. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020, Jul;146(1):203–06.e3. https://doi.org/10.1016/j.jaci.2020.04.009
20. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020, Jul;202(1): 83–90. https://doi.org/10.1164/rccm.202003-0821OC
21. Ostovar A, Fokkens WJ, Pordel S, Movahed A, Ghasemi K, Marzban M, et al. The prevalence of asthma in adult population of southwestern Iran and its association with chronic rhinosinusitis: A GA 2 LEN study. Clin Transl Allergy. 2019;9(1):43. https://doi.org/10.1186/s13601-019-0283-6
22. Garg S. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep (MMWR). 2020 Apr;69(15):458–64. http://dx.doi.org/10.15585/mmwr.mm6915e3
23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, Feb;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585